Live tape
Top 8, mentions 7d13,810NVDA3,450 mentions▲ +0.04GOOGL2,420 mentions▲ +0.04AMD1,805 mentions▲ +0.08SPY1,573 mentions▲ +0.06QQQ1,572 mentions▲ +0.05SPCX1,069 mentions▲ +0.05TSLA986 mentions▲ +0.05AAPL935 mentions▲ +0.05

Equity · Healthcare

AGIO

NASDAQ

Agios Pharmaceuticals (AGIO)

29.38 USD +4.26% vs prior close
Agios Pharmaceuticals, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for AGIO to draw a line in its place.

Track this symbol on TradingView
Market cap
1.8B USD
Revenue, year to Dec 2025
54.0M USD
EPS, diluted, year to Dec 2025
−7.12 USD
52-week range
23 USD – 45.46 USD
Avg volume
74.3K

as of Nov 6, 2026

Have Agios Pharmaceuticals (AGIO) insiders bought or sold shares recently?

AGIO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 26 October 2026.

Form 4

Have Agios Pharmaceuticals (AGIO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
26 Oct 2026Gheuens SarahChief Medical OfficerSell7,866296K USD
22 Oct 2026Gheuens SarahChief Medical OfficerSell50019K USD
21 Oct 2026Gheuens SarahChief Medical OfficerSell1,48956K USD
04 Aug 2026Gheuens SarahChief Medical OfficerSell30,000914K USD
01 Jul 2026Gheuens SarahChief Medical OfficerSell4,007151K USD
02 Apr 2026Goff BrianChief Executive OfficerSell19,068662K USD
02 Apr 2026Viswanadhan KrishnanChief Corp Dev & StrategySell2,959103K USD
02 Apr 2026Milanova TsvetaChief Commercial OfficerSell3,262113K USD
02 Apr 2026Jones CeciliaChief Financial OfficerSell3,141109K USD
02 Apr 2026Gheuens SarahChief Medical OfficerSell2,940102K USD
02 Apr 2026Burns James WilliamChief Legal OfficerSell3,280114K USD
05 Mar 2026Viswanadhan KrishnanChief Corp Dev & StrategySell2,95982K USD
Sold30 open-market sales163,856$5.14M

Showing the 12 most recent of 30 open-market trades in this window. The figures above count all of them.

39 other filings: grants, exercises, tax withholding and transfers, not trades
Have Agios Pharmaceuticals (AGIO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
26 Oct 2026Gheuens SarahChief Medical OfficerOption exercise7,866197K USD
22 Oct 2026Gheuens SarahChief Medical OfficerOption exercise50013K USD
21 Oct 2026Gheuens SarahChief Medical OfficerOption exercise1,48937K USD
08 Jul 2026Backstrom Jay T.DirectorAward1,447
01 Jul 2026Gheuens SarahChief Medical OfficerOption exercise8,375
18 Jun 2026Smith CynthiaDirectorOption exercise2,816
18 Jun 2026Scadden DavidDirectorOption exercise2,816
18 Jun 2026Owen Adams CatherineDirectorOption exercise2,816
18 Jun 2026Ho MaykinDirectorOption exercise2,816
18 Jun 2026FOUSE JACQUALYN ADirectorOption exercise2,816
18 Jun 2026Foster-Cheek Kaye IDirectorOption exercise2,816
18 Jun 2026CAPELLO JEFFREY DDirectorOption exercise2,816

Showing the 12 most recent of 39 compensation filings in this window. The figures above count all of them.

Which funds hold Agios Pharmaceuticals (AGIO)?

8 of the 45 institutional funds we track reported a Agios Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 218.8M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Agios Pharmaceuticals (AGIO)?
FundPositionSharesValueShares q/q
D. E. Shaw & Co.Held (±25%)3,107,005115.3M USD+15.9%
Citadel AdvisorsHeld (±25%)732,68727.2M USD+18.2%
AQR Capital ManagementAdded684,34025.4M USD+1,779.5%
Two Sigma InvestmentsAdded536,38019.9M USD+113.2%
Point72 Asset ManagementNew position506,34418.8M USD
Marshall WaceTrimmed138,8005.2M USD−69.0%
Man GroupHeld (±25%)124,4664.6M USD−13.7%
Tudor Investment CorpHeld (±25%)65,7792.4M USD+13.1%
Balyasny Asset ManagementExited
Millennium ManagementExited

Have members of Congress traded Agios Pharmaceuticals (AGIO)?

The most recent congressional trade disclosed in Agios Pharmaceuticals is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 20 Aug 2026.

STOCK Act disclosures

Have members of Congress traded Agios Pharmaceuticals (AGIO)?
TradedMemberTypeAmountFiled after
20 Aug 2026Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD21 days
03 Mar 2026Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD35 days
17 Apr 2025Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD19 days
29 Jan 2025Gilbert Ray Cisneros, Jr.house · Democrat–CAPurchase1K USD–15K USD13 days
24 Jan 2024Josh Gottheimerhouse · Democrat–NJPurchase1K USD–15K USD22 days

What has been filed or recorded for Agios Pharmaceuticals (AGIO)?

The filings we hold for Agios Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Agios Pharmaceuticals (AGIO)?
And
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −1.09 USD
30 Sep 2026FinancialsTotal assets1.1B USDat period end
30 Sep 2026FinancialsTotal equity979.3M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.69 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.69 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −7.12 USD
31 Dec 2025FinancialsRevenue54.0M USDfiscal year
31 Dec 2025FinancialsNet income−412.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−7.12 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.78 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −1.93 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.55 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 11.64 USD

Agios Pharmaceuticals (AGIO): frequently asked questions

From live data
1.8B

What is Agios Pharmaceuticals’ market cap?

Agios Pharmaceuticals is worth 1.8B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.

54.0M

What is Agios Pharmaceuticals’ revenue?

Agios Pharmaceuticals reported revenue of 54.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Agios Pharmaceuticals insiders bought or sold shares recently?

No Agios Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 26 Oct 2026 (SEC Form 4). See Insiders

8 of 45

Which funds own Agios Pharmaceuticals?

8 of the 45 funds we track reported a Agios Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Citadel Advisors and AQR Capital Management. See Funds

5 trades

Have members of Congress traded Agios Pharmaceuticals?

Yes. 5 trades in Agios Pharmaceuticals appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 20 Aug 2026, filed 10 Sep 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

−1.09

When did Agios Pharmaceuticals last report earnings?

Agios Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.09 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings